Jefferies Maintains Hold on Nektar Therapeutics, Raises Price Target to $1
Portfolio Pulse from Benzinga Newsdesk
Jefferies analyst Roger Song maintains a Hold rating on Nektar Therapeutics (NKTR) and raises the price target from $0.5 to $1.
March 06, 2024 | 2:44 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Jefferies analyst Roger Song maintains a Hold rating on Nektar Therapeutics and raises the price target from $0.5 to $1.
The increase in price target by Jefferies suggests a positive outlook on NKTR's value, potentially leading to increased investor interest and a short-term positive impact on the stock price. The Hold rating indicates a view that the stock is currently valued appropriately, but the raised target suggests an expectation of some upward movement.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 100